Palisade Bio raises $6M in registered direct offering and private placement at $2.64/share

PALISADE BIO, INC.

Gross proceeds of ~$6.0M from sale of 2,272,723 shares/pre-funded warrants at $2.64 per share.
Includes 756,317 registered shares, unregistered shares/pre-funded warrants, and 2,272,723 common warrants (exercise $2.64, 5-year term).
Ladenburg Thalmann acted as placement agent; net proceeds for working capital and general corporate purposes.
Offering closed on April 5, 2023.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PALISADE BIO, INC. entered into Purchase Agreements with certain institutional and accredited investors valued at aggregate gross proceeds to the Company of approximately $6.0 million (effective 2023-04-03).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional and accredited investors
Value: aggregate gross proceeds to the Company of approximately $6.0 million
Effective: 2023-04-03

Exact text from the filing

On April 3, 2023, Palisade Bio, Inc. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional and accredited investors (the “Purchasers”)

View on SEC.gov

283 material agreements filed in the last 30 days. Browse all material agreements →

PALISADE BIO, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-011066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.